Intravenous Iron and Hypophosphatemia in Patients with Iron Deficiency Anemia

Rates of hypophosphatemia were higher with ferric carboxymaltose than with ferric derisomaltose.

Ferric carboxymaltose (FC) and ferric derisomaltose (FD) are intravenous iron formulations that were developed to rapidly correct iron deficiency anemia (IDA) in patients who are intolerant or resistant to oral iron. Prior studies have shown that the use of FC is associated with hypophosphatemia due to increased urinary loss mediated by increased concentrations of fibroblast growth factor 23. Other studies have suggested that the risk for hypophosphatemia is lower with FD than with FC. However, no head-to-head comparisons of the two formulations have been conducted.

Now, investigators report the results of two identically designed, multicenter, open-label, randomized trials that compared the incidence of hypophosphatemia with FC versus FD in…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Intravenous Iron and Hypophosphatemia in Patients with Iron Deficiency Anemia

Topics

Reviewing Author